Effects of L-Arginine and Citrulline Malate Supplementation on Sport Performance in Physically Active Men (ReachSci)

April 14, 2025 updated by: Leonidas Petridis, Hungarian University of Sports Science

Acute Effects of Combined Supplementation of L-Arginine and Citrulline Malate on Aerobic, Anaerobic, and CrossFit® Exercise Performance

In this randomized, double-blind, placebo-controlled trial we investigated the effects of combined L-arginine (Arg) and citrulline-malate (CM) supplementation on aerobic, anaerobic, and high-intensity interval training in healthy, physically active men. 46 healthy, physically active men were divided into three distinct exercise protocol groups: CrossFit group, the Wingate Anaerobic Test group, and the Harvard Step Test group. The CrossFit performance assessment involved the "Cindy" workout, a high-intensity protocol composed of bodyweight exercises organized in a set sequence: 5 pull-ups, 10 push-ups, and 15 squats. Participants were instructed to perform as many rounds as possible within 20 minutes. The Wingate Anaerobic test involved a 30-second all-out cycling test on a bike ergometer, while the Harvard Step Test The Harvard Step Test was conducted using a 51 cm high platform, with participants stepping at a rate of 30 steps per minute (one second up, one second down) for five minutes or until exhaustion. Each participant attended three separate laboratory sessions. The initial session served for familiarization with the test protocol to minimize learning effects. In the second and the third sessions, participants attended two measurement sessions, conducted in randomized order and under double-blind conditions, where they received either the dietary supplementation or a placebo. Each participant acted as their control, allowing for within-subject comparisons.

Study Overview

Detailed Description

Consumption of dietary supplements is a common strategy among athletes aiming to optimize recovery after training or competitions and enhance athletic performance. Amino acids L-arginine (Arg) and L-citrulline (Cit) are two of the most widely used supplements in recent times. Their use as nutritional supplements or dietary supplements to improve health and athletic performance has increased dramatically, as both Arg and Cit are essential for the body's synthesis of nitric oxide (NO) and elimination of waste products such as lactate during physical activity. Because it functions as an endogenous precursor to Arg, the primary substrate of nitric oxide, Cit, a non-protein, non-essential amino acid, has attracted a lot of attention lately for its potential to improve exercise performance. Commonly, citrulline is consumed as citrulline malate (CM), which is a mixture of Cit and malic acid in ratios ranging from 1:1 to 2:1. The combined intake of Arg and CM could potentially enhance athletic performance more effectively than using either supplement alone. This synergistic benefit is attributed to Cit's role in synthesizing additional Arg, which in turn elevates NO production, enhancing blood flow and possibly reducing muscle fatigue. Supporting this hypothesis, mixed supplementation of Arg and CM was examined in a previous study and significant increases in both force exertion and fatigue resistance during a 10-minute high-intensity cycling test was found. However, while initial evidence suggests potential ergogenic benefits of combined Arg and CM supplementation, further research is needed to confirm these effects across various exercise modalities. The aim of this study was to investigate the acute effects of combined Arg and CM supplementation on anaerobic performance, aerobic performance, or both through high-intensity interval training (i.e. CrossFit) outcomes in healthy, physically active men. Based on existing research, it was hypothesized that the supplementation would enhance performance by achieving higher peak power in the anaerobic protocol and CrossFit in the CrossFit training protocol, where rapid energy production and resistance to fatigue are critical.

Study Type

Interventional

Enrollment (Actual)

46

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Budapest, Hungary, 1124
        • Hungaria University of Sports Science

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • being healthy, physically active with no history of injuries or illnesses at the time of measurement or within the preceding six months

Exclusion Criteria:

  • consumption of any dietary supplements in the last six months to avoid confounding effects

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Supplementation
Supplementation of L-Arginine and Citrulline-malate as a liquid
L-Arginine and Citrulline Malate supplementation was consumed as a liquid one single time to examine the acute effects on sport performance
Placebo Comparator: Placebo
Consumption of a placebo liquid
Consumption of placebo as a liquid

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mechanical Power
Time Frame: Day 1 and Day 2
Maximal and mean mechanical power was assessed during the Wingate Anaerobic Test under both conditions (supplementation and placebo).
Day 1 and Day 2
Fitness Score
Time Frame: Day 1 and Day 2
During the CrossFit exercise and the Harvard Step Test the primare measure of performance was a Fitness Score, which was calculated from the rounds completed for the CrossFit exercise and from the time duration and heart rate for the Harvard Step Test.
Day 1 and Day 2

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Heart Rate
Time Frame: Day 1 and Day 2
Maximal and mean heart rate was measured for all three exercise protolcols: The Wingate Anaerobic Test, The CrossFit Test, and the Harvard Step Test.
Day 1 and Day 2

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2023

Primary Completion (Actual)

May 15, 2024

Study Completion (Actual)

September 30, 2024

Study Registration Dates

First Submitted

April 7, 2025

First Submitted That Met QC Criteria

April 14, 2025

First Posted (Actual)

April 22, 2025

Study Record Updates

Last Update Posted (Actual)

April 22, 2025

Last Update Submitted That Met QC Criteria

April 14, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • TE-KEB/22/2023
  • HungarianUSportsScience (Other Identifier: Hungarian University of Sports Science)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All individual data the are included in the study and support the statistical analysis

IPD Sharing Time Frame

from April 1, 2025 to December 31, 2025

IPD Sharing Access Criteria

Data are available by the corresponding author

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Study Data/Documents

  1. Individual Participant Data Set
    Information identifier: TE-KEB/22/2023
    Information comments: For more information please email to: petridis.leonidas@tf.hu

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe